Safety and efficacy of fidaxomicin in patients with clostridium difficile infection

Monica A. Donnelley, Jeremiah J. Duby, Christine S Cocanour

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Fidaxomicin is a bactericidal macrolide that is indicated for the treatment of Clostridium difficile infection (CDI) in adults. Fidaxomicin is not effective for the treatment of systemic infections due to minimal systemic absorption. Until recently, oral vancomycin was the only medication with United States Food and Drug Administration (FDA) approval for the treatment of CDI. In clinical studies, fidaxomicin demonstrated noninferiority to vancomycin for the treatment of CDI. Lower recurrence rates of CDI with fidaxomicin than with oral vancomycin were observed. The lower recurrence rates were not observed with highly virulent strains of C. difficile. Lower recurrence rates of CDI with fidaxomicin are believed to be associated with its narrow spectrum of activity. Fidaxomicin was approved for use after publication of the most recent guideline from the Society for Healthcare Epidemiology of America (SHEA) and Infectious Diseases Society of America (IDSA). However, its current place in clinical practice is unknown. The cost of fidaxomicin should be considered when prescribing this medication.

Original languageEnglish (US)
Pages (from-to)75-79
Number of pages5
JournalClinical Medicine Insights: Therapeutics
Volume5
DOIs
StatePublished - 2013

Fingerprint

Clostridium Infections
Clostridium difficile
Safety
Vancomycin
Recurrence
Drug Approval
Macrolides
United States Food and Drug Administration
Therapeutics
lipiarmycin
Publications
Guidelines
Costs and Cost Analysis
Infection

Keywords

  • CDI
  • Clostridium difficile
  • Efficacy
  • Fidaxomicin
  • Infection
  • Safety
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmaceutical Science
  • Pharmacology

Cite this

Safety and efficacy of fidaxomicin in patients with clostridium difficile infection. / Donnelley, Monica A.; Duby, Jeremiah J.; Cocanour, Christine S.

In: Clinical Medicine Insights: Therapeutics, Vol. 5, 2013, p. 75-79.

Research output: Contribution to journalArticle

@article{b9405b3e6a584c6cb0a01a78ed9b43c3,
title = "Safety and efficacy of fidaxomicin in patients with clostridium difficile infection",
abstract = "Fidaxomicin is a bactericidal macrolide that is indicated for the treatment of Clostridium difficile infection (CDI) in adults. Fidaxomicin is not effective for the treatment of systemic infections due to minimal systemic absorption. Until recently, oral vancomycin was the only medication with United States Food and Drug Administration (FDA) approval for the treatment of CDI. In clinical studies, fidaxomicin demonstrated noninferiority to vancomycin for the treatment of CDI. Lower recurrence rates of CDI with fidaxomicin than with oral vancomycin were observed. The lower recurrence rates were not observed with highly virulent strains of C. difficile. Lower recurrence rates of CDI with fidaxomicin are believed to be associated with its narrow spectrum of activity. Fidaxomicin was approved for use after publication of the most recent guideline from the Society for Healthcare Epidemiology of America (SHEA) and Infectious Diseases Society of America (IDSA). However, its current place in clinical practice is unknown. The cost of fidaxomicin should be considered when prescribing this medication.",
keywords = "CDI, Clostridium difficile, Efficacy, Fidaxomicin, Infection, Safety, Treatment",
author = "Donnelley, {Monica A.} and Duby, {Jeremiah J.} and Cocanour, {Christine S}",
year = "2013",
doi = "10.4137/CMT.S7279",
language = "English (US)",
volume = "5",
pages = "75--79",
journal = "Clinical Medicine Insights: Therapeutics",
issn = "1179-559X",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Safety and efficacy of fidaxomicin in patients with clostridium difficile infection

AU - Donnelley, Monica A.

AU - Duby, Jeremiah J.

AU - Cocanour, Christine S

PY - 2013

Y1 - 2013

N2 - Fidaxomicin is a bactericidal macrolide that is indicated for the treatment of Clostridium difficile infection (CDI) in adults. Fidaxomicin is not effective for the treatment of systemic infections due to minimal systemic absorption. Until recently, oral vancomycin was the only medication with United States Food and Drug Administration (FDA) approval for the treatment of CDI. In clinical studies, fidaxomicin demonstrated noninferiority to vancomycin for the treatment of CDI. Lower recurrence rates of CDI with fidaxomicin than with oral vancomycin were observed. The lower recurrence rates were not observed with highly virulent strains of C. difficile. Lower recurrence rates of CDI with fidaxomicin are believed to be associated with its narrow spectrum of activity. Fidaxomicin was approved for use after publication of the most recent guideline from the Society for Healthcare Epidemiology of America (SHEA) and Infectious Diseases Society of America (IDSA). However, its current place in clinical practice is unknown. The cost of fidaxomicin should be considered when prescribing this medication.

AB - Fidaxomicin is a bactericidal macrolide that is indicated for the treatment of Clostridium difficile infection (CDI) in adults. Fidaxomicin is not effective for the treatment of systemic infections due to minimal systemic absorption. Until recently, oral vancomycin was the only medication with United States Food and Drug Administration (FDA) approval for the treatment of CDI. In clinical studies, fidaxomicin demonstrated noninferiority to vancomycin for the treatment of CDI. Lower recurrence rates of CDI with fidaxomicin than with oral vancomycin were observed. The lower recurrence rates were not observed with highly virulent strains of C. difficile. Lower recurrence rates of CDI with fidaxomicin are believed to be associated with its narrow spectrum of activity. Fidaxomicin was approved for use after publication of the most recent guideline from the Society for Healthcare Epidemiology of America (SHEA) and Infectious Diseases Society of America (IDSA). However, its current place in clinical practice is unknown. The cost of fidaxomicin should be considered when prescribing this medication.

KW - CDI

KW - Clostridium difficile

KW - Efficacy

KW - Fidaxomicin

KW - Infection

KW - Safety

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84875424605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875424605&partnerID=8YFLogxK

U2 - 10.4137/CMT.S7279

DO - 10.4137/CMT.S7279

M3 - Article

VL - 5

SP - 75

EP - 79

JO - Clinical Medicine Insights: Therapeutics

JF - Clinical Medicine Insights: Therapeutics

SN - 1179-559X

ER -